MCM
TSHA icon

MAI Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

MAI Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$59 Buy
13
+5
+63% +$23 ﹤0.01% 4843
2025
Q4 		$44 Buy
+8
New +$39 ﹤0.01% 4252

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MAI Capital Management's TSHA Position: Q1 2026 in Review

MAI Capital Management increased its Taysha Gene Therapies (TSHA) stake by 63% in Q1 2026, buying an estimated $23 and bringing the position to 13 shares worth $59. The position accounts for ﹤0.01% of the portfolio, ranked #4843.

MAI Capital Management first reported a position in TSHA in Q4 2025 and has held it in 2 quarters since. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • MAI Capital Management held 13 shares of Taysha Gene Therapies worth $59 as of Q1 2026.
  • MAI Capital Management bought 5 Taysha Gene Therapies shares in Q1 2026, an estimated $23.
  • Taysha Gene Therapies made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4843 holding.
  • MAI Capital Management first reported a position in Taysha Gene Therapies in Q4 2025 and has held it in 2 quarters since.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.